SNOW - Forget Snowflake! Buy This Ultra-High-Growth Stock
When cloud data company Snowflake (NYSE: SNOW) went public last month, it captured investors' imaginations with incredible sales growth, well-known backers, and a tremendous first-day rise in stock price. But at a valuation of well over 120 times sales -- more than 80 times that of the median S&P 500 stock -- much of the company's bright future is already priced in.
Investors who want to participate in that kind of hyper-growth, but are worried they missed out on Snowflake, may find the same captivating potential in early-stage biotech stocks such as Vaxart (NASDAQ: VXRT) . The vaccine maker, which used an unusual merger and reverse stock split to go public in February 2018, could offer life-changing returns for investors willing to take a risk before the company's technology hits the market. While the downside is obvious -- the company could go bust -- success would mean astronomical growth from its current $780 million market cap.
Image source: Getty Images.
For further details see:
Forget Snowflake! Buy This Ultra-High-Growth Stock